Christoph J Griessenauer1, Christopher S Ogilvy1, Paul M Foreman2, Michelle H Chua3, Mark R Harrigan2, Lucy He4, Matthew R Fusco4, J D Mocco5, Christopher J Stapleton6, Aman B Patel6, Ashish Sonig7, Adnan H Siddiqui7, Ajith J Thomas1. 1. Neurosurgical Service, Beth Israel Dea-coness Medical Center, Harvard Medic-al School, Boston, Massachusetts. 2. Dep-artment of Neurosurgery, University of Alabama at Birmingham, Birmingham, Alabama. 3. Harvard Medical School, Bost-on, Massachusetts. 4. Department of Neur-osurgery, Vanderbilt University, Nashville, Tennessee. 5. Department of Neurosu-rgery, Mount Sinai Hospital, New York, New York. 6. Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 7. Department of Neurosurgery, Univ-ersity at Buffalo, Buffalo, New York.
Abstract
BACKGROUND: To date, the use of the flow-diverting Pipeline Embolization Device (PED) for small intracranial aneurysms (≤ 7 mm) has been reported only in single-center series. OBJECTIVE: To evaluate the safety and efficacy of the PED in a multicenter cohort. METHODS: Five major academic institutions in the United States provided data on patient demographics, aneurysm features, and treatment characteristics of consecutive patients with aneurysms ≤ 7 mm treated with a PED between 2009 and 2015. Radiographic outcome was assessed with digital subtraction angiography. Clinical outcome was measured with the modified Rankin Scale. RESULTS: The cumulative number of aneurysms ≤ 7 mm treated with PED at the 5 institutions was 149 in 117 patients (age, 54 years [range, 29-87 years]; male to female, 1-5.9). Aneurysms were most commonly located in the paraophthalmic segment (67.1%) of the internal carotid artery. Radiographic outcome at last follow-up was available for 123 aneurysms (82.6%), with a complete occlusion rate of 87%. Thromboembolic and symptomatic procedural complications occurred in 8.7% and 6% of the aneurysms treated, respectively. There was 1 mortality (0.9%) unrelated to the PED procedure. Multivariable logistic regression identified size < 4 mm, balloon angioplasty to open the device, and simultaneous treatment of multiple aneurysms as predictors of procedural complications. Good clinical outcome was achieved in 96% of electively treated patients. CONCLUSION: In the largest series on PED for small aneurysms to date, data suggest that treatment with the flow-diverting PED is safe and efficacious, with complication rates comparable to those for traditional endovascular techniques.
BACKGROUND: To date, the use of the flow-diverting Pipeline Embolization Device (PED) for small intracranial aneurysms (≤ 7 mm) has been reported only in single-center series. OBJECTIVE: To evaluate the safety and efficacy of the PED in a multicenter cohort. METHODS: Five major academic institutions in the United States provided data on patient demographics, aneurysm features, and treatment characteristics of consecutive patients with aneurysms ≤ 7 mm treated with a PED between 2009 and 2015. Radiographic outcome was assessed with digital subtraction angiography. Clinical outcome was measured with the modified Rankin Scale. RESULTS: The cumulative number of aneurysms ≤ 7 mm treated with PED at the 5 institutions was 149 in 117 patients (age, 54 years [range, 29-87 years]; male to female, 1-5.9). Aneurysms were most commonly located in the paraophthalmic segment (67.1%) of the internal carotid artery. Radiographic outcome at last follow-up was available for 123 aneurysms (82.6%), with a complete occlusion rate of 87%. Thromboembolic and symptomatic procedural complications occurred in 8.7% and 6% of the aneurysms treated, respectively. There was 1 mortality (0.9%) unrelated to the PED procedure. Multivariable logistic regression identified size < 4 mm, balloon angioplasty to open the device, and simultaneous treatment of multiple aneurysms as predictors of procedural complications. Good clinical outcome was achieved in 96% of electively treated patients. CONCLUSION: In the largest series on PED for small aneurysms to date, data suggest that treatment with the flow-diverting PED is safe and efficacious, with complication rates comparable to those for traditional endovascular techniques.
Authors: N Adeeb; C J Griessenauer; A A Dmytriw; H Shallwani; R Gupta; P M Foreman; H Shakir; J Moore; N Limbucci; S Mangiafico; A Kumar; C Michelozzi; Y Zhang; V M Pereira; C C Matouk; M R Harrigan; A H Siddiqui; E I Levy; L Renieri; T R Marotta; C Cognard; C S Ogilvy; A J Thomas Journal: AJNR Am J Neuroradiol Date: 2018-06-07 Impact factor: 3.825
Authors: Samuel Pearce; Julian T Maingard; Hong Kuan Kok; Christen D Barras; Jeremy H Russell; Joshua A Hirsch; Ronil V Chandra; Ash Jhamb; Vincent Thijs; Mark Brooks; Hamed Asadi Journal: Clin Neuroradiol Date: 2021-03-01 Impact factor: 3.649
Authors: N Adeeb; J M Moore; M Wirtz; C J Griessenauer; P M Foreman; H Shallwani; R Gupta; A A Dmytriw; R Motiei-Langroudi; A Alturki; M R Harrigan; A H Siddiqui; E I Levy; A J Thomas; C S Ogilvy Journal: AJNR Am J Neuroradiol Date: 2017-09-14 Impact factor: 3.825
Authors: N Adeeb; J M Moore; C J Griessenauer; P M Foreman; H Shallwani; A A Dmytriw; H Shakir; A H Siddiqui; E I Levy; J M Davies; M R Harrigan; A J Thomas; C S Ogilvy Journal: AJNR Am J Neuroradiol Date: 2017-05-18 Impact factor: 3.825
Authors: Anna Luisa Kühn; Peter Kan; Nils Henninger; Visish Srinivasan; Katyucia de Macedo Rodrigues; Ajay K Wakhloo; Matthew J Gounis; Ajit S Puri Journal: J Clin Neurosci Date: 2019-05-06 Impact factor: 1.961
Authors: Tessa A Harland; Joshua Seinfeld; Andrew C White; David A Kumpe; Christopher D Roark; David E Case Journal: J Vasc Interv Neurol Date: 2020-01
Authors: Axel Rosengart; Malie K Collins; Philipp Hendrix; Ryley Uber; Melissa Sartori; Abhi Jain; Jennifer Mao; Oded Goren; Clemens M Schirmer; Christoph J Griessenauer Journal: Interv Neuroradiol Date: 2021-02-04 Impact factor: 1.764